ERBB3 and melanoma: A recent report further demonstrates that over-expression of HER3 is associated with a poorer survival rate in patients with cancers, including colorectal cancer, gastric cancer, breast cancer, melanoma, ovarian cancer, head and neck cancer, pancreatic cancer and cervical cancer [36].